Bladder carcinoma (BC) is one of the most common malignant cancers worldwide. Several genes related to the mechanism of BC have been studied in recent years, but the current understanding of BC is still rather limited. This study aimed to find new differentially expressed genes (DEGs) associated with the occurrence and development of BC.
Methods
In this work, we downloaded gene expression data from Gene Expression Omnibus under accession number GSE27448, which included 10 GeneChips from urinary BC tissues and 5 from normal tissues. DEGs were identified by the LIMMA package in R. Then the protein-protein interactions (PPIs) networks were analyzed with the database of Search Tool for the Retrieval of Interacting Genes, and gene ontology (GO) was applied to explore the underlying function of the DEGs using the Database for Annotation, Visualization and Integrated Discovery.
Results
A total of 2,068 DEGs were found between BC and normal tissues. These genes were involved in 49 functional clusters. The top 10 highest degree nodes, such as POLR2F/2H (DNA directed RNA polymerase II polypeptide F/polypeptide H) and RPS14/15 (ribosomal protein S14/S15), were proven to be hub nodes in the PPIs network. ITGA7 (integrin, alpha 7), GRB14 (growth factor receptor-bound protein 14), CDC20 (cell division cycle 20) and PSMB1 (proteasome subunit, beta type, 1) were significant DEGs identified in the functional clusters.
Conclusions
Genes such as POLR2F/2H, RPS14/15, ITGA7, GRB14, CDC20 and PSMB1 were forecast to play important roles in the occurrence and progression of BC.
WeltonJ.L., KhannaS., GilesP.J.. Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics.2010; 9(6): 1324–1338.
2.
DaiQ.S., HeH.C., CaiC.. [Multicenter case-control study of the relationship between smoking and bladder cancer in China] [article in Chinese]. Zhonghua Yi Xue Za Zhi.2011; 91(34): 2407–2410.
ParkinD.M.The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl.2008; 42(218): 12–20.
5.
JemalA., BrayF., CenterM.M., FerlayJ., WardE., FormanD.Global cancer statistics. CA Cancer J Clin.2011; 61(2): 69–90.
6.
Sánchez-CarbayoM., Cordon-CardóC.Molecular alterations associated with bladder cancer progression. In: Seminars in oncology.Philadelphia: Elsevier; 2007.
7.
Cordon-CardoC.Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl.2008; 42(218): 154–165.
8.
ChatterjeeS.J., DatarR., YoussefzadehD.. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol.2004; 22(6): 1007–1013.
9.
ShariatS.F., TokunagaH., ZhouJ.. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol.2004; 22(6): 1014–1024.
10.
ZaravinosA., LambrouG.I., BoulalasI., DelakasD., SpandidosD.A.Identification of common differentially expressed genes in urinary bladder cancer. PLoS ONE.2011; 6(4): e18135.
11.
FujitaA., SatoJ.R., RodriguesL.O., FerreiraC.E., SogayarM.C.Evaluating different methods of microarray data normalization. BMC Bioinformatics.2006; 7(1): 469.
12.
BolstadB.M., IrizarryR.A., AstrandM., SpeedT.P.A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics.2003; 19(2): 185–193.
13.
SmythG.K.Limma: linear models for microarray data. In: Bioinformatics and computational biology solutions using R and Bioconductor.New York: Springer; 2005: 397–420.
14.
BenjaminiY., HochbergY.Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol.1995; 57(1): 289–300.
15.
StelzlU., WormU., LalowskiM.. A human protein-protein interaction network: a resource for annotating the proteome. Cell.2005; 122(6): 957–968.
16.
JensenL.J., KuhnM., StarkM.. STRING 8: a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res.2009; 37(Database issue): D412–D416.
17.
OzgürA., VuT., ErkanG., RadevD.R.Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics.2008; 24(13): i277–i285.
18.
HulseggeI., KommadathA., SmitsM.A.Globaltest and GOEAST: two different approaches for Gene Ontology analysis. BMC Proc, 3 Suppl 4: S10, 2009.
19.
HuangW., ShermanB.T., LempickiR.A.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc.2009; 4(1): 44–57.
20.
FerlayJ., BrayF., PisaniP., ParkinD.: GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5. version 2.0. Lyon, France: IARCPress;2004; 195: 2007.
21.
PloegM., AbenK.K., KiemeneyL.A.The present and future burden of urinary bladder cancer in the world. World J Urol.2009; 27(3): 289–293.
22.
LiX., ShenS., WuM.. Transcriptomic regulation and molecular mechanism of polygenic tumor at different stages. Journal of Central South University. Med Sci.2011; 36: 585.
23.
VoyantC., BiffiK., LeschiD., BriançonJ., LantieriC.Dosimetric uncertainties related to the elasticity of bladder and rectal walls: adenocarcinoma of the prostate. Cancer Radiother.2011; 15(4): 270–278.
24.
HeX., ZhangJ.Why do hubs tend to be essential in protein networks?PLoS Genet.2006; 2(6): e88.
25.
AntonacopoulouA.G., GrivasP.D., SkarlasL., KalofonosM., ScopaC.D., KalofonosH.P.POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance?Anticancer Res.2008; 28(2B): 1221–1227.
26.
HouseleyJ., TollerveyD.The many pathways of RNA degradation. Cell.2009; 136(4): 763–776.
27.
KimJ.H., KimH.N., LeeK.T.. Gene expression profiles in gallbladder cancer: the close genetic similarity seen for early and advanced gallbladder cancers may explain the poor prognosis. Tumour Biol.2008; 29(1): 41–49.
28.
MasicaD.L., KarchinR.Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res.2011; 71(13): 4550–4561.
29.
RouquetteJ., ChoesmelV., GleizesP.E.Nuclear export and cytoplasmic processing of precursors to the 40S ribosomal subunits in mammalian cells. EMBO J.2005; 24(16): 2862–2872.
30.
GerbiS.A., BorovjaginA.V.Pre-ribosomal RNA processing in multicellular organisms. In: The Nucleolus.New York: luwer Academic/Plenum Publishers; 2004: 170–198.
DaftuarL., ZhuY., JacqX., PrivesC.Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS ONE.2013; 8(7): e68667.
33.
WalterR.B., ObermoellerR.D., MooreD.D.. Characterization and mapping of the Xiphophorus maculatus (Teleostei: Poeciliidae) RPS15 gene. Cytogenet Cell Genet.1996; 75(2-3): 140–144.
34.
LaiM.D., XuJ.Ribosomal proteins and colorectal cancer. Curr Genomics.2007; 8(1): 43–49.
35.
LuY., LiuP., Van den BerghF.. Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer. Cancer Prev Res (Phila).2012; 5(2): 248–259.
36.
WallerandH., CaiY., WainbergZ.A.. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. In: Urologic oncology: seminars and original investigations.Philadelphia: Elsevier; 2010.
37.
De GroatW.C., YoshimuraN.Afferent nerve regulation of bladder function in health and disease. In: Sensory nerves.Berlin Heidelberg: Springer; 2009: 91–138.
38.
SongT., ZhangX., WangC.. Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev.2011; 12(4): 929–933.
YuY.P., LuoJ.H.Phosphorylation and interaction of myopodin by integrin-link kinase lead to suppression of cell growth and motility in prostate cancer cells. Oncogene.2011; 30(49): 4855–4863.
41.
CariouB., BereziatV., MoncoqK.. Regulation and functional roles of Grb14. Front Biosci.2004; 9(1-3): 1626–1636.
42.
BaiT., LuohS.W.GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. Carcinogenesis.2008; 29(3): 473–479.
43.
DalyR.J., SandersonG.M., JanesP.W., SutherlandR.L.Cloning and characterization of GRB14, a novel member of the GRB7 gene family. J Biol Chem.1996; 271(21): 12502–12510.
44.
KramerE.R., ScheuringerN., PodtelejnikovA.V., MannM., PetersJ.M.Mitotic regulation of the APC activator proteins CDC20 and CDH1. Mol Biol Cell.2000; 11(5): 1555–1569.
45.
KidokoroT., TanikawaC., FurukawaY., KatagiriT., NakamuraY., MatsudaK.CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene.2008; 27(11): 1562–1571.
46.
PaulT.I., DelwelH.R.Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer.2004. EP Patent 1,393,776.
47.
KeutgensA., ZhangX., ShostakK.. BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit pSMB1. J Biol Chem.2010; 285(33): 25831–25840.
48.
TaylorI.W., LindingR., Warde-FarleyD.. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol.2009; 27(2): 199–204.
